Portfolio Companies News
September 17, 2021Vicore starts dosing of first COVID...
Gothenburg, September 17, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today announces the dosing of the first patients in the company’s global phase 3 trial of C21 in COVID-19 (ATTRACT-3). ... read more
September 16, 2021Targovax ASA: Poster at European So...
Describing the role of ONCOS-102 in combination with aPD1 in aPD1 refractory, advanced or unresectable melanoma Oslo, Norway, 16 September 2021 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, todayannounces... read more
September 14, 2021Nordic Nanovector Appoints Experien...
Oslo, Norway, 14 September 2021 Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Erik Skullerud as Chief Executive Officer (CEO). He will take up the position on 20 September 2021 and will be based in the company's office in Zug, Switzerland, splitting his time between Zug and Nor... read more
September 14, 2021Aprea Therapeutics to Present Data ...
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presenta... read more
September 13, 2021Precirix and IFE sign clinical tria...
Brussels, Belgium and Kjeller, Norway, 13 September 2021 – Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and the Institute for Energy Technology (IFE), a manufacturer of radiopharmaceutical products based in Norway today announced an agreem... read more
July 22, 2021Q2 2021 General Market Overview
Since the start in 1996, HealthCap funds have invested in 122 portfolio companies.
46 of the portfolio companies have been taken public on nine different markets.
27 of the portfolio companies pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.